FREMONT, Calif., May 11, 2016 /PRNewswire/ -- Neurocentria, Inc. announced today the publication of a scientific paper showing how its candidate drug, L­-Threonic acid Magnesium salt (L-TAMS), reverses cognitive impairment in humans, as previously demonstrated. The paper titled "Regulation of structural and functional synapse density by L-threonate through modulation of intraneuronal magnesium concentration" was published in the medical journal Neuropharmacology. The drug's discovery is based on more than a decade of research at Stanford, Tsinghua University, and MIT.

"We believe identifying the molecular mechanism of action for our drug - which we've shown to be effective in reversing cognitive deficits in humans with Mild Cognitive Impairment (MCI) - opens exciting possibilities for the company," says Guosong Liu, M.D., Ph.D., and CEO of Neurocentria, Inc. "These new results, along with our other publications, provide a robust scientific foundation to explain our positive published human trial on MCI and support our ongoing trials on Alzheimer's Disease at Stanford University, Schizophrenia at Northwestern University, and Adult ADHD at Harvard University," says Liu.

Previously, on October 28, 2015, the Company published a paper demonstrating L-TAMS significantly reversed cognitive deficits in 50-70 year old subjects with Mild Cognitive Impairment, a condition that increases by up to 10-fold the risk of developing Alzheimer's Disease. There is currently no FDA-approved drug to treat or prevent Mild Cognitive Impairment. Published in the Journal of Alzheimer's Disease, the blinded, controlled clinical trial demonstrated with high statistical significance (p <0.01) that L-TAMS, after 12 weeks of intake, improved cognitive ability as determined by a composite test of four major cognitive domains, reversing the equivalent of 9 years of cognitive aging.

The current study provides a scientific explanation for how the drug works. The Company had discovered that intraneuronal magnesium is a critical regulator of synaptic density and plasticity, critical factors that determine cognitive ability. In this paper, Neurocentria showed that L-threonate, a component of the drug, drives magnesium into the fluids that surround the brain (cerebrospinal fluid), and then into neurons. This then leads to multiple changes including enhanced synaptic density and plasticity. Other magnesium salts lacking L-threonate failed to have the same results. The Company also identified the molecular transporters responsible for the drug's action, opening windows to develop the next generation of drugs.

Market Insights:

Alzheimer's and the high-risk condition that precedes it, Mild Cognitive Impairment, together affect more than 11 million Americans.

In 2016, Alzheimer's will cost the nation $236 billion , and is expected to rise to $1.1 trillion by 2050 according to the Alzheimer's Association.

To learn more about Neurocentria's breakthrough published human trial for reversing Mild Cognitive Impairment, contact Julianne Diaz, [email protected]

About Neurocentria, Inc. Neurocentria is a biopharmaceutical company that is developing innovative treatments for cognitive impairment associated with aging, neurological diseases like Alzheimer's and psychiatric conditions like Schizophrenia and Adult ADHD. The drug's discovery is based on more than a decade of research at Stanford, Tsinghua University, and MIT. Neurocentria was founded by a former MIT professor, Guosong Liu M.D. Ph.D., and a renowned chemist and inventor of molecular diagnostics, Fei Mao Ph.D.

SOURCE Neurocentria, Inc.

Related Links

http://www.neurocentria.com

